GBS Venture Partners (GBS) is a leading life science venture capital firm.
Founded in 1996, GBS invests in young businesses developing and commercialising products which, when combined with the right management and finance, will make a significant difference to patients' lives and deliver financial returns for our investors. Our areas of particular interest and expertise include human healthcare, biotechnology product development and life science start-ups. In particular, recent investments have included biological or small molecule therapeutics, medical devices and diagnostics.
GBS invests in private or public companies whether at start-up or later stages of company development. Our investors include major Australian superannuation funds.
GBS manages over $400 million across five funds. In March 2009, GBS completed a fund raising for GBS Bioventures IV, a $125 million fund which has the capacity to invest up to $10 – 12 million per investee. Previous funds include:
- The Australian Bioscience Trust
- GBS Bioventures II
- The Genesis Fund
- GBS Bioventures III
GBS uses these and other funds under management to make a significant commitment to building life science based companies based on Australasian technology and development capabilities.
Active Support Role
The GBS team use their experience in life science investing to:
- take an active role at board level in portfolio companies
- provide strategic advice and support at all stages of company development
- access specialist scientific and technical advice and introductions to international contacts and corporate collaborators
The GBS team has been investing in Australasia since 1996 and has financed companies with a combined market capitalisation approaching $2 billion.